SB Investment Advisers (UK)’s Roivant Sciences ROIV Stock Holding History

SB Investment Advisers (UK)’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$74M	Sell	2,671,732 -13,741,871	-84%	-$353M	0.96%	7
2025 Q4	$356M	Sell	16,413,603 -23,901,524	-59%	-$472M	3.56%	3
2025 Q3	$610M	Sell	40,315,127 -19,637,525	-33%	-$243M	4.6%	3
2025 Q2	$676M	Sell	59,952,652 -1,900,066	-3%	-$20.6M	5.36%	3
2025 Q1	$624M	Sell	61,852,718 -204,819	-0.3%	-$2.21M	5.69%	3
2024 Q4	$734M	Sell	62,057,537 -3,876,537	-6%	-$45.8M	6.45%	3
2024 Q3	$761M	Sell	65,934,074 -5,427,314	-8%	-$61.8M	6.27%	3
2024 Q2	$754M	Sell	71,361,388 -1,670,279	-2%	-$18.3M	6.97%	3
2024 Q1	$770M	Hold	73,031,667	–	–	7.6%	4
2023 Q4	$820M	Hold	73,031,667	–	–	7.3%	4
2023 Q3	$853M	Sell	73,031,667 -10,000,000	-12%	-$113M	7.03%	3
2023 Q2	$837M	Hold	83,031,667	–	–	6.38%	4
2023 Q1	$613M	Sell	83,031,667 -12,000,000	-13%	-$98.8M	5.04%	4
2022 Q4	$759M	Sell	95,031,667 -4,343,919	-4%	-$24.2M	6.33%	4
2022 Q3	$320M	Hold	99,375,586	–	–	2.45%	6
2022 Q2	$404M	Hold	99,375,586	–	–	3.21%	8
2022 Q1	$491M	Hold	99,375,586	–	–	2.33%	9
2021 Q4	$1B	Buy	+99,375,586	New	+$827M	2.92%	6

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SB Investment Advisers (UK)'s ROIV Position: Q1 2026 in Review

SB Investment Advisers (UK) reduced its Roivant Sciences (ROIV) stake by 84% in Q1 2026, selling an estimated $353M and leaving 2,671,732 shares worth $74M. The position accounts for 0.96% of the portfolio, ranked #7.

SB Investment Advisers (UK) first reported a position in ROIV in Q4 2021 and has held it in 18 quarters since. The position peaked at $1B in Q4 2021. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

SB Investment Advisers (UK) held 2,671,732 shares of Roivant Sciences worth $74M as of Q1 2026.
SB Investment Advisers (UK) sold 13,741,871 Roivant Sciences shares in Q1 2026, an estimated $353M.
Roivant Sciences made up 0.96% of SB Investment Advisers (UK)'s portfolio in Q1 2026, its #7 holding.
SB Investment Advisers (UK) first reported a position in Roivant Sciences in Q4 2021 and has held it in 18 quarters since.
SB Investment Advisers (UK)'s Roivant Sciences position peaked at $1B in Q4 2021.
440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on SB Investment Advisers (UK)'s 13F filing for Q1 2026, filed 18 May 2026.